Table 3 Safety and tolerance within the first 7 days following treatment initiation
Tolerance issues | Total n = 80 | Standard of care n = 22 | Lopinavir/ritonavir n = 20 | Hydroxy-chloroquine n = 38 | p value |
|---|---|---|---|---|---|
Neutropenia, n (%) | 1 (1) | 0 (0) | 1 (5) | 0 (0) | 0.219 |
Anemia, n (%) | 7 (9) | 2 (9) | 2 (10) | 3 (8) | 0.962 |
Thrombocytopenia, n (%) | 10 (13) | 2 (9) | 3 (15) | 5 (13) | 0.834 |
Increased aspartate aminotransferase > 5 N, n (%) | 20 (25) | 6 (27) | 7 (35) | 7 (18) | 0.367 |
Increased alanine aminotransferase > 5 N, n (%) | 14 (18) | 3 (14) | 3 (15) | 8 (21) | 0.724 |
Acute renal failure KDIGO ≥ 2, n (%) | 40 (50) | 12 (55) | 12 (60) | 16 (42) | 0.381 |
Prolonged QT interval*, n (%) | 1 (1) | 0 (0) | 0 (0) | 1 (3) | 0.571 |